OAM
AKBA icon

Oxford Asset Management’s Akebia Therapeutics AKBA Stock Holding History

Oxford Asset Management’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-100,047
Closed -$161K – 450
2025
Q4 		$161K Buy
+100,047
New +$209K 0.06% 405
2024
Q2 		– Sell
-22,262
Closed -$40.7K – 277
2024
Q1 		$40.7K Buy
+22,262
New +$35.6K 0.04% 248
2019
Q4 		– Sell
-91,571
Closed -$359K – 1725
2019
Q3 		$359K Sell
91,571
-30,445
-25% -$130K 0.01% 1401
2019
Q2 		$591K Sell
122,016
-62,676
-34% -$357K 0.01% 1201
2019
Q1 		$1.51M Sell
184,692
-146,287
-44% -$1M 0.03% 725
2018
Q4 		$1.83M Buy
+330,979
New +$2.59M 0.05% 513
2018
Q3 		– Sell
-116,062
Closed -$1.12M – 1669
2018
Q2 		$1.12M Sell
116,062
-31,048
-21% -$311K 0.02% 976
2018
Q1 		$1.4M Sell
147,110
-27,642
-16% -$387K 0.03% 767
2017
Q4 		$2.61M Sell
174,752
-29,708
-15% -$493K 0.06% 447
2017
Q3 		$4M Buy
204,460
+135,460
+196% +$2.08M 0.08% 289
2017
Q2 		$992K Buy
+69,000
New +$875K 0.02% 891

Other funds holding AKBA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Oxford Asset Management's AKBA Position: Q1 2026 in Review

Oxford Asset Management sold out of Akebia Therapeutics (AKBA) in Q1 2026, closing a stake of 100,047 shares — an estimated $161K sold.

Oxford Asset Management first reported a position in AKBA in Q2 2017 and held it in 11 quarters. The position peaked at $4M in Q3 2017. 171 funds tracked by Wall St. Rank hold AKBA as of Q1 2026.

  • Oxford Asset Management reported no remaining Akebia Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Oxford Asset Management sold 100,047 Akebia Therapeutics shares in Q1 2026, an estimated $161K.
  • Oxford Asset Management first reported a position in Akebia Therapeutics in Q2 2017 and held it in 11 quarters.
  • Oxford Asset Management's Akebia Therapeutics position peaked at $4M in Q3 2017.
  • 171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2026.

Based on Oxford Asset Management's 13F filing for Q1 2026, filed 15 May 2026.